NEW YORK, June 2 (GenomeWeb News) - Iconix Pharmaceuticals will provide chemogenomic profiling services for AstraZeneca, the company said today.


Under the agreement, Mountain View, Calif.-based Iconix will profile compounds from AstraZeneca for toxicity using its Drug Signatures library, a collection of predictive biomarkers derived from its chemogenomics reference database.


To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.